投融资数据库
免费查数据
注册送3天会员
首页>投融资
Neuron23
D轮
Neuron23 Inc, owned by Origenis GmbH operates as a biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. The company leverages recent advances in human genetics, combined with their state-of-the-art artificial intelligence (AI)-enabled drug discovery and biomarker platforms, to advance therapeutics for devastating diseases, providing patients with the right medicines suffering from genetic disorders.In March 2022, Neuron23 Inc closed a $100 million Series C financing round led by SoftBank Vision Fund 2, bringing the company's total financing to $213.5 million.In December 2020, the company announced that it had closed USD 113.5 million Series A (USD 33.5 million) and B (USD 80 million) financing. The Series A was led by Westlake Village BioPartners, and Kleiner Perkins, and Series B was led by Redmile Group. Other Series B investors include Westlake Village BioPartners, Kleiner Perkins, Cowen Healthcare Investments, Acorn
基本信息
-
公司全称Neuron23 Inc
-
类型遗传疾病治疗用小分子药物研发商
-
产业领域医药研发/制造、化学&生物药
-
公司人数51~100人
-
地址681 Gateway Blvd. 3rd Floor SOUTH SAN FRANCISCO CALIFORNIA 94080; US; Telephone: +13104038951;
-
联系电话310-403-8951
-
邮箱info.mail@neuron23.com
-
成立时间2018-01-01
投融资
-
2025-06-24
-
2022-03-30
-
2020-12-16
-
2020-12-16
- 加载更多
相关投融资企业
PreA轮
苏州时安生物技术有限公司成立于2022年5月5日，位于苏州工业园区。公司是一家专注于创新siRNA（小干扰RNA）药物开发的生物技术企业。其核心技术包括eSAFE化学修饰技术和STORK肝内肝外递送技术平台，致力于开发抗病毒、心血管及代谢类疾病、自身免疫、中枢神经系统等相关疾病的小核酸药物管线。
A轮
Axoltis Pharma (formerly Neuronax) is a biopharmaceutical company established in 2003 and focused on the R&D of potential therapeutics for neural repair in neurotraumas, central nervous system disorders and neurodegenerative disorders. It aims to seek outlicensing or codevelopment partners to further its technologies,,.In May 2019, the company changed its corporate name from Neuronax to Axoltis Pharma,.In April 2012, the EMA extended its Small and Medium Sized Enterprises status qualification and provided incentives.Axoltis is a biopharmaceutical company with headquarters in Clermont-Ferrand, France,.By November 2013, the company had raised EUR 1 million (US $1.352 million) through series A financing
未公开
重庆汉佩生物科技有限公司成立于2022年9月22日，是一家专注于宠物药物研发和生产的生物科技企业。公司由药学专家、药物研发人员、临床、注册人员等组成专业团队，聚焦宠物创新药及宠物仿制药的开发。公司拥有GC-MS、LC-MS、UPLC、HPLC等先进科研仪器设备，致力于解决中国市场未被满足的宠物药物临床需求。公司在湖北省宜昌市生物医药园区内设有医药化工中试生产基地，可满足高温、高压、超低温、高真空等各式极端反应，已成功开发了系列宠物药物，包括针对慢性炎症、疼痛、心血管、肿瘤等老年常见病药物。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息